CG Oncology (CGON) Non Operating Income (2023 - 2026)

CG Oncology has reported Non Operating Income for 4 years, with the latest figure at -$101000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 101.3% year-over-year to -$101000.0; the trailing twelve-month figure through Mar 2026 stood at $21.9 million (down 48.14% YoY), and the FY2025 full-year result was $29.8 million, up 11.84% from the prior year.
• Non Operating Income for Q1 2026 stood at -$101000.0, down from $7.4 million in the prior quarter.
• The five-year high for Non Operating Income was $26.6 million in Q4 2024, with the low at -$101000.0 in Q1 2026.
• Historically, Non Operating Income has averaged $5.9 million across 4 years, with a median of $5.5 million in 2024.
• Annual changes were most pronounced in 2025 — Non Operating Income jumped 91337.5% — and 2026, when it slumped 101.3%.
• CG Oncology's Non Operating Income stood at $2.8 million in 2023, then soared by 851.07% to $26.6 million in 2024, then sank by 72.25% to $7.4 million in 2025, then slumped by 101.37% to -$101000.0 in 2026.
• The last three Non Operating Income figures came in at -$101000.0 (Q1 2026), $7.4 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.